Kolon Life Science announced on April 2 that its affiliate, Kolon TissueGene, has recently secured a series of patent registrations for the "mixed cell gene therapy" of TG-C, an osteoarthritis gene therapy under development, in several Asian countries.


Kolon Life Science headquarters. Kolon Life Science

Kolon Life Science headquarters. Kolon Life Science

View original image

This patent covers the "mixed cell gene therapy" technology, which involves administering both cells engineered to produce growth factors (TGF-β or BMP) and cells that respond to these signals to exert therapeutic effects. TG-C is administered by combining two solutions: one containing chondrocytes and the other containing genetically modified cells.


The Asian regional patent was granted in the Philippines and Malaysia last month, following Indonesia in February this year. Kolon Life Science is responsible for local development and commercialization of TG-C in Asia.


According to the company, TG-C is currently in the final stages of a Phase 3 clinical trial for knee osteoarthritis in the United States. Kolon TissueGene, which is conducting the U.S. clinical trial for TG-C, aims to release topline results in July, after completing two years of follow-up and data analysis. Based on this, the company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of next year.



Lee Hankook, CEO of Kolon Life Science, stated, "This patent registration is significant as it concretizes the rights to the core design and technology of TG-C mixed cell gene therapy in major Asian markets," adding, "We will accelerate preparations for local development and commercialization going forward."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing